NCM
SNDX icon

Nantahala Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Nantahala Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-754,503
Closed -$7.07M – 170
2025
Q2 		$7.07M Buy
754,503
+200,000
+36% +$2.2M 0.28% 72
2025
Q1 		$6.81M Sell
554,503
-6,029
-1% -$85K 0.27% 57
2024
Q4 		$7.41M Buy
560,532
+107,300
+24% +$1.84M 0.32% 58
2024
Q3 		$8.72M Hold
453,232
– – 0.44% 45
2024
Q2 		$9.3M Sell
453,232
-12,027
-3% -$252K 0.54% 37
2024
Q1 		$11.1M Buy
465,259
+100,000
+27% +$2.23M 0.63% 33
2023
Q4 		$7.89M Buy
365,259
+125,228
+52% +$1.92M 0.47% 47
2023
Q3 		$3.49M Sell
240,031
-83,103
-26% -$1.57M 0.3% 73
2023
Q2 		$6.76M Sell
323,134
-652,571
-67% -$13.6M 0.65% 38
2023
Q1 		$20.6M Hold
975,705
– – 1.58% 16
2022
Q4 		$24.8M Sell
975,705
-399,723
-29% -$9.32M 1.61% 14
2022
Q3 		$33.1M Sell
1,375,428
-1,287,659
-48% -$28.9M 2.14% 11
2022
Q2 		$51.2M Sell
2,663,087
-29,216
-1% -$487K 2.57% 6
2022
Q1 		$46.8M Sell
2,692,303
-158,256
-6% -$2.66M 2.07% 13
2021
Q4 		$62.4M Buy
2,850,559
+193,400
+7% +$3.57M 2.2% 9
2021
Q3 		$50.8M Buy
2,657,159
+63,822
+2% +$1.06M 1.6% 20
2021
Q2 		$44.5M Buy
2,593,337
+590,927
+30% +$10.8M 1.27% 20
2021
Q1 		$44.8M Buy
2,002,410
+203,957
+11% +$4.61M 1.31% 21
2020
Q4 		$40M Buy
1,798,453
+459,762
+34% +$9.53M 1.24% 19
2020
Q3 		$19.8M Buy
+1,338,691
New +$20.4M 0.6% 35

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Nantahala Capital Management's SNDX Position: Q3 2025 in Review

Nantahala Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 754,503 shares — an estimated $7.07M sold.

Nantahala Capital Management first reported a position in SNDX in Q3 2020 and held it in 20 quarters. The position peaked at $62.4M in Q4 2021. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Nantahala Capital Management reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 754,503 Syndax Pharmaceuticals shares in Q3 2025, an estimated $7.07M.
  • Nantahala Capital Management first reported a position in Syndax Pharmaceuticals in Q3 2020 and held it in 20 quarters.
  • Nantahala Capital Management's Syndax Pharmaceuticals position peaked at $62.4M in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Nantahala Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.